Back to results
US 6,743,425 B2Granted
Therapeutic agents for achondroplasia
AssigneeKazuwa Nakao
InventorKazuwa Nakao
Life of this patent
Estimating the term…
Abstract
The present invention aims to provide novel therapeutic agents for achondroplasia caused by mutations in FGFR3. Therapeutic agents for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3), comprising a substance activating guanylyl cyclase B (GC-B) as an active ingredient are disclosed.
Claims5
A method for treating achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3), comprising administering a substance activating guanylyl cyclase B (GC-B).
Dependencies are inferred from the claim text.